C-HCT0Pentraxin Therapeutics
SAP depletion, amyloid immunotherapy, CRP inhibition
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HCT0
C-HCT0C-HCT0SAP depletion, amyloid immunotherapy, CRP inhibition
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Pentraxin Therapeutics SAP depletion, amyloid immunotherapy, CRP inhibition
Pentraxin Therapeutics Ltd is described as a University College London spin-out company founded in 2001 by Professor Sir Mark Pepys FRS. The company holds intellectual property and proprietary knowledge created by Sir Mark and his research group. Its R&D programs focus on systemic amyloidosis and serum amyloid P component, SAP targeting in Alzheimer's disease, C-reactive protein inhibition, and SAP depletion for DNA vaccination.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Pentraxin Therapeutics — Far from goals · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (3 programs at undisclosed).…
Source: Deterministic